Biotechnology

By Maggie Fox, health and science editor Maggie Fox, health and science Editor-Mountain Nov 22, 6: 19 h. HITTITES WASHINGTON (Reuters)-Christopher Goodrich, Portland, Oregon, can't wait for a needle in his eyes. Goodrich was expected to be one of the first patients were enrolled in clinical trial this only a sound States food and drug administration, only the second judgment approved anywhere in the world test globil human milk stem in the people. Advanced cell technology, a Massachusetts-based company biotechnologie did evil to bring globil human milk stem in the lab to the clinic, recrutement 12 patients start in Oregon, Massachusetts and eye condition called scarce Stargardt (k will be put to death. Goodrich, 55, retired last year of his work as Coordinator for services to the University of Portland State when Stargardt (k death completely inexplicable and suddenly take a turn for the worse. Like most patients Goodrich, saw the vision, it gets worse steadily from his earliest da...

WASHINGTON-Biotech drugmaker Amgen says, federal health regulators approved the consolidation of the bone and taking drugs cracking with Advanced cancer patients-in order to prevent the problems. Food and Drug Administration has not been selected patients with solid tumours of the company's drug denosumab. THE FDA approved the three studies, which revealed, it will not be able to work with at least as well as Novartis ' bone complications related to Zometa abatement on the basis of the drug. Amgen sells already with the name of the drug, but Prolia osteoporosis caused by the treatment of Menopause. The company markets its new drug for use in Xgeva. More than 50% of cancer patients experience problems cancer spreads to the bones, according to the company. Doctors manage Xgeva once in the month following that in which the injection patients. The drug works by blocking the installation of bone protein, which cells. View the original article here